Can atorvastatin cause gynaecomastia? It is a reasonable question given that atorvastatin is one of the most widely prescribed statins in the UK, used daily by millions of men to reduce cardiovascular risk. Gynaecomastia — the development of glandular breast tissue in men — has a broad range of causes, and understanding whether a commonly taken medication could be responsible is important. This article examines the current evidence, explores the theoretical biological mechanisms, identifies who may be at greater risk, and explains when to seek medical advice from your GP or pharmacist.

Atorvastatin and Gynaecomastia: What the Evidence Shows

Gynaecomastia is not a confirmed side effect of atorvastatin; isolated post-marketing case reports exist but no causal link has been established in controlled clinical data.

Experiencing these side effects? Our pharmacists can help you navigate them →

Atorvastatin is one of the most widely prescribed statins in the UK, used to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiovascular events such as heart attack and stroke. It works by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. Given how commonly it is prescribed, questions about its potential side effects — including gynaecomastia (the development of glandular breast tissue beneath the areola in men) — are understandable.

It is worth briefly distinguishing true gynaecomastia, which involves proliferation of glandular tissue and is hormonally driven, from pseudogynaecomastia, which is fatty tissue deposition in the chest without glandular involvement and is not hormonally mediated. This distinction matters clinically, as the two conditions have different causes and management pathways.

Regarding atorvastatin specifically, gynaecomastia is not listed as a common adverse effect in the current UK Summary of Product Characteristics (SmPC) for atorvastatin, as held on the MHRA/electronic Medicines Compendium (eMC). A small number of post-marketing case reports have described gynaecomastia in men taking statins, including atorvastatin; where such reports exist, they are typically classified under 'frequency unknown' in post-marketing surveillance, meaning causality has not been established from controlled data. These are isolated observations rather than findings from large, controlled clinical trials.

There is therefore no confirmed causal link between atorvastatin and gynaecomastia at this time. However, the absence of a confirmed link does not make an association impossible. Because statins interact with cholesterol metabolism — and cholesterol is a precursor to sex hormones — a theoretical biological mechanism exists, even if it has not been conclusively demonstrated in clinical practice. Any man who notices breast swelling or tenderness whilst taking atorvastatin should report this to their GP or pharmacist for proper evaluation. If you believe atorvastatin may have caused a side effect, you can also report this directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Worried about interactions with other medications? Speak to one of our pharmacists →

How Statins May Affect Hormone Levels in Men

Statins inhibit cholesterol synthesis, and because cholesterol is a precursor to sex hormones, modest testosterone reductions have been observed in some studies, though clinical significance for most men remains uncertain.

To understand why statins have been theoretically associated with hormonal changes, it helps to consider their mechanism of action more closely. Atorvastatin inhibits the mevalonate pathway, which is central to cholesterol biosynthesis. Because cholesterol is the biochemical precursor to all steroid hormones — including testosterone, oestrogen, and cortisol — there has been scientific interest in whether long-term statin use could subtly alter the hormonal environment in men.

Some observational studies and systematic reviews (published in journals such as the Journal of Clinical Endocrinology and Metabolism and the European Journal of Endocrinology) have suggested that statin use may be associated with modest reductions in total testosterone levels in men. However, findings across studies are inconsistent, the average changes reported are generally small, and the clinical significance for most men remains uncertain. Importantly, current UK regulatory guidance from the MHRA and clinical guidance from NICE do not identify hypogonadism or clinically meaningful androgen suppression as a recognised risk of statin therapy.

A reduction in testosterone relative to oestrogen could, in principle, shift the androgen-to-oestrogen ratio in a direction that promotes glandular breast tissue development — the fundamental hormonal imbalance underlying true gynaecomastia. However, several important caveats apply:

• Most large clinical trials of statins have not reported gynaecomastia as a significant adverse event.

• The hormonal changes observed in some studies are generally small and may not be clinically meaningful for the majority of men.

• Individual factors such as age, body composition, liver function, alcohol intake, and concurrent medications can all influence hormone metabolism independently of statin use.

In summary, whilst a plausible biological mechanism exists, the clinical evidence does not currently support the conclusion that atorvastatin routinely causes meaningful hormonal disruption leading to gynaecomastia. Research in this area is ongoing, and healthcare professionals should remain alert to patient-reported symptoms.

How Common Is This Side Effect and Who Is at Risk

Gynaecomastia attributable to atorvastatin is considered rare; men who are older, obese, have liver disease, or take multiple medications carry a higher baseline risk of developing gynaecomastia from any cause.

Based on current evidence, gynaecomastia attributable to atorvastatin appears to be rare. It is not listed as a common side effect (affecting more than 1 in 100 people) in the current UK atorvastatin SmPC (MHRA/eMC). Where post-marketing reports of gynaecomastia have been associated with statins, these are typically classified as 'frequency unknown', reflecting that causality and incidence cannot be reliably estimated from spontaneous reports alone. The well-recognised side effects of atorvastatin include muscle aches (myalgia), elevated liver enzymes, headache, gastrointestinal disturbances, and — rarely — a serious muscle condition called rhabdomyolysis.

Certain groups of men may be more vulnerable to developing gynaecomastia in general, and these individuals might be more likely to notice or report breast changes whilst taking any medication:

• Older men: Testosterone levels naturally decline with age, altering the androgen-to-oestrogen balance.

• Men with obesity: Adipose (fat) tissue converts androgens to oestrogens via aromatase activity, increasing oestrogen levels; this group is also more prone to pseudogynaecomastia.

• Men with liver disease: The liver metabolises sex hormones; impaired liver function can lead to oestrogen accumulation.

• Men with alcohol excess: Heavy alcohol use can impair hepatic hormone metabolism and suppress testosterone.

• Men taking multiple medications: Polypharmacy is common in those prescribed statins, and other drugs in the regimen may be the true cause of gynaecomastia.

• Men with hypogonadism or other endocrine conditions: Pre-existing hormonal imbalances increase baseline risk.

• Men receiving exogenous hormone therapy: Including testosterone replacement or androgen-deprivation therapy.

For most healthy men taking atorvastatin at standard doses (10–80 mg daily), the likelihood of developing gynaecomastia solely as a result of the statin is considered very low. Nevertheless, any new or unexplained breast changes should always be investigated to rule out other causes, including malignancy.

Other Medicines and Conditions That Can Cause Gynaecomastia

Spironolactone, digoxin, anti-androgens, and certain antipsychotics have stronger established associations with gynaecomastia than atorvastatin, and underlying conditions such as hypogonadism or liver disease are also common causes.

When a man taking atorvastatin develops gynaecomastia, it is essential to consider the full clinical picture before attributing the symptom to the statin. Gynaecomastia is a relatively common condition with a wide range of causes, and in many cases, another explanation is more likely.

Medications with well-established or strong associations with gynaecomastia include:

• Spironolactone (a diuretic with anti-androgenic properties) — one of the most frequently implicated drugs

• Digoxin — used in heart failure and atrial fibrillation

• Cimetidine — a histamine H2 receptor antagonist

• Anabolic steroids and testosterone therapy — paradoxically, exogenous androgens can convert to oestrogens via aromatase

• Anti-androgens such as finasteride, bicalutamide, and GnRH analogues (used in prostate cancer treatment)

• Androgen-deprivation therapy — a well-recognised cause in men treated for prostate cancer

• Oestrogens — including those used therapeutically

• Ketoconazole — an antifungal that inhibits androgen synthesis

• Efavirenz — an antiretroviral used in HIV treatment

• Certain antipsychotics — particularly those that raise prolactin levels, such as risperidone and paliperidone; evidence is stronger for antipsychotics than for antidepressants as a class

• Proton pump inhibitors — a weak and controversial association has been reported in some case series; evidence is limited and this should not be over-interpreted

Underlying medical conditions that can cause gynaecomastia include:

• Hypogonadism (primary or secondary)

• Hyperthyroidism

• Chronic liver disease or cirrhosis

• Chronic kidney disease

• Adrenal or testicular tumours

• Klinefelter syndrome

Physiological gynaecomastia can also occur during puberty and in older age without any identifiable pathological cause.

Given this broad differential, a GP will typically take a thorough medication and alcohol history, examine the patient (including testicular examination where indicated), and arrange blood tests — including testosterone, oestradiol, LH, FSH, prolactin, beta-hCG (where a tumour is suspected), thyroid function, and liver and renal function — before drawing any conclusions about causation. Breast imaging and testicular ultrasound may be arranged where clinical findings warrant further assessment. NICE CKS guidance on gynaecomastia provides detailed primary-care investigation and referral thresholds.

When to Speak to Your GP or Pharmacist

Men taking atorvastatin who notice breast swelling, a lump, nipple discharge, or skin changes should seek prompt GP assessment; unilateral or suspicious features require urgent referral under NICE NG12.

If you are taking atorvastatin and notice any changes in your breast tissue — such as swelling, tenderness, a lump, or nipple discharge — it is important to seek medical advice promptly. Whilst gynaecomastia is usually benign, breast changes in men should never be dismissed without proper assessment, as male breast cancer, though rare, does occur.

You should contact your GP if you experience:

• Unilateral (one-sided) breast swelling or a firm, irregular lump — this requires prompt evaluation to exclude malignancy

• Skin or nipple changes, such as puckering, dimpling, or inversion

• Nipple discharge, particularly if bloodstained

• Breast changes accompanied by other symptoms such as unexplained weight loss, fatigue, or testicular changes

• Breast tenderness that is persistent, worsening, or significantly affecting your quality of life

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), men presenting with suspicious breast features — such as a hard, irregular unilateral mass, bloody nipple discharge, skin or nipple changes, or palpable axillary lymph nodes — should be referred urgently via the 2-week-wait suspected cancer pathway. If your GP considers your symptoms to meet these criteria, they will arrange an urgent referral to a specialist breast service.

Your pharmacist can help by:

• Reviewing your full medication list to identify other drugs more commonly associated with gynaecomastia

• Advising whether it is safe to continue atorvastatin whilst awaiting a GP appointment

• Signposting you to appropriate NHS resources

Do not stop taking atorvastatin without speaking to a healthcare professional first. Statins provide important cardiovascular protection, and abruptly discontinuing treatment could increase your risk of a serious cardiac event. Your GP can assess whether the statin is likely to be contributing to your symptoms and, if necessary, consider switching to an alternative statin or adjusting your treatment plan. NICE NG238 (Cardiovascular Disease: Risk Assessment and Lipid Modification, 2023) emphasises the importance of shared decision-making in lipid management, and your concerns should always be taken seriously.

Managing Your Cholesterol Treatment Safely

Do not stop atorvastatin without medical advice; options include watchful waiting, switching to an alternative statin, reviewing other causative medications, or specialist referral for persistent gynaecomastia.

For the vast majority of men, atorvastatin is a safe, well-tolerated, and highly effective medication that significantly reduces the risk of cardiovascular disease. The benefits of statin therapy — particularly in those with established heart disease or high cardiovascular risk — are well-supported by robust clinical evidence and endorsed by NICE NG238, the NHS, and major cardiology organisations.

If you or your GP suspect that atorvastatin may be contributing to gynaecomastia, there are several management options to consider:

• Watchful waiting: In mild cases, monitoring the situation whilst continuing treatment may be appropriate, particularly if no other cause is identified and the symptom is not distressing.

• Switching statins: Different statins have slightly different pharmacological profiles. Pravastatin and rosuvastatin, for example, are more hydrophilic than atorvastatin and may have a different side-effect profile, though evidence specifically comparing gynaecomastia risk between individual statins is limited. Any switch should maintain an appropriate intensity of lipid-lowering therapy in line with NICE NG238 recommendations.

• Reviewing the full medication regimen: Identifying and addressing other causative drugs may resolve the issue without any change to statin therapy.

• Treating the underlying cause: If an endocrine condition is identified, treating it directly may resolve the gynaecomastia.

• Specialist referral: Persistent, painful, or distressing gynaecomastia that does not resolve with conservative measures may warrant referral to an endocrinologist or breast clinic. Definitive treatments — such as tamoxifen or surgical correction — are specialist-led and considered only in appropriate cases.

It is also worth maintaining a healthy lifestyle alongside medication — a balanced diet, regular physical activity, achieving a healthy body weight, and limiting alcohol intake all support cardiovascular health and can help manage cholesterol levels. If you have concerns about any aspect of your cholesterol treatment, speak openly with your GP or a pharmacist. Informed, shared decision-making is central to safe and effective long-term management.

If you believe atorvastatin or any other medicine has caused a side effect, you are encouraged to report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. This helps regulators monitor the safety of medicines in real-world use.

Frequently Asked Questions